Vera Therapeutics reports preliminary cash of $160.7M; suspends ATM offering

Vera Therapeutics, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2023: approximately $160.7 million.
Company suspended and terminated the ATM prospectus effective Jan 29, 2024; no further sales under current Sales Agreement until new prospectus filed.
Estimate is unaudited and subject to change upon completion of quarter-end and year-end financial close for Q4 and FY2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.